Octant

Octant stands at the forefront of the Biotechnology and Life Sciences sectors, leveraging cutting-edge technologies to transform drug discovery. Founded in 2017 and headquartered in the United States, Octant focuses on developing synthetic technology and applying next-generation DNA sequencing, gene synthesis, and gene editing.

The company's slogan, "Developing synthetic technology and applying next-generation DNA sequencing, gene synthesis, and gene editing to discover safer, more effective, cheaper drugs," succinctly encapsulates its mission. Octant's innovative approach combines advanced cell engineering, high-throughput chemistry, and automation to engineer best-in-class drugs targeting rare diseases, oncology, and immunology.

Having secured an $80.00M Series B investment on 01 April 2022, Octant is well-backed by notable investors such as Fifty Years, Andreessen Horowitz\/ a16z, Allen & Company, Bristol-Meyers Squibb, and Catalio Capital Management. This strong financial support underscores the company's potential to redefine drug discovery and delivery.